Hopp til innhold
NHI.no
Annonse

Livmorhalskreft: Viktig med god informasjon

Innhold i artikkelen

Still spørsmål! Det er viktig at du forstår begrunnelsen for de råd som legen gir. Ved å engasjere deg i sykdommen og behandlingen sikrer du deg den beste hjelp.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Livmorhalskreft . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft. Livmorhalskreft. Oslo: mai 2020. IS-2854 www.helsedirektoratet.no
  2. Kristensen GB. Oncolex. Sist revidert mars 2017. oncolex.no
  3. Kreftregisteret. Cancer in Norway 2018. Oslo: Kreftregisteret, 2019. www.kreftregisteret.no.
  4. Danckert B, Ferlay J, Engholm G et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019). Hentet 30.04.19 www.ancr.nu
  5. Berland J, Bjørge T, Chen Y, et al. Kvalitetsmanual - Masseundersøkelsen mot livmorhalskreft. Kreftregisteret. Revidert utgave mai 2014. www.kreftregisteret.no
  6. Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB et al. Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival. Gynecol Oncol. 2017;145(3):543–548. pmid:28356187 PubMed
  7. World Health Organization. Comprehensive cervical cancer control. A guide to essential practice. Second edition. Geneva: WHO; 2014. www.who.int
  8. Ferlay J, Ervik M, Lam F et al (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Hentet 30.04.19 gco.iarc.fr
  9. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370 (9590): 890. pmid: 7826171 PubMed
  10. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354: 2645-54. pmid:16790697 PubMed
  11. Jensen KE, Thomsen LT, Schmiedel S. Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study. Sex Transm Infect 2014. PMID: 24728044 PubMed
  12. Kaderli R, Schnüriger B, Brügger LE. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis 2014. pmid:24935346 PubMed
  13. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-80. PMID: 16835323 PubMed
  14. Sun V, Chang L, Rutherford GW. Human papillomavirus (HPV) vaccine for individuals with HIV infection (Protocol). Cochrane Database of Syst Rev 2013. doi:10.1002/14651858.CD010493 DOI
  15. Wipperman J, Neil T, Williams T. Cervical Cancer: Evaluation and Management. Am Fam Physician. 2018;97(7):449–454. PMID: 29671552 PubMed
  16. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.. Lancet 2007; 370 (9599): 1609. pmid:17993361 PubMed
  17. Andreassen T, Vogt C. Screening for livmorhalskreft i endring. Tidsskr Nor Legeforen 2014; 134: 1122-3.
  18. Nama V, Angelopoulos G, Twigg J et al. Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer. Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No.: CD011478. DOI: 10.1002/14651858.CD011478.pub2 DOI
  19. Penson RT, Huang HQ, Wenzel LB et al.. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial. Lancet 2015; 16: 301-11. pmid:25638326 PubMed
  20. Amant F, Halaska MJ, Fumagalli M et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer 2014;24(3):394–403. PMID: 24445819 PubMed
  21. Falcetta FS, Medeiros LRF, Edelweiss MI et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD005342. DOI: 10.1002/14651858.CD005342.pub4 DOI
  22. Kokka F, Bryant A, Brockbank E, Jeyarajah A. Surgical treatment of stage IA2 cervical cancer. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD010870. DOI: 10.1002/14651858.CD010870.pub2 DOI
  23. Sia TY, Chen L, Melamed A, et al. Trends in use and effect on survival of simple hysterectomy for early-stage cervical cancer. Obstet Gynecol 2019; 134: 1132-43. pmid:31764721 PubMed
  24. Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N ENgl J Med 2020; 383: 1340-48. pmid:32997908 PubMed
  25. McCredie MR, Sharples KJ, Paul C et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-34. pmid:18407790 PubMed
  26. Helsedirektoratet. Seneffekter etter kreftbehandling. Faglige råd. Oslo: Helsedirektoratet; 2017. IS-2551 oslo-universitetssykehus.no
  27. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaeceol Obstet 2018; 143: 22-36. pmid:30306584 PubMed
  28. Straughn JM. Yashar C, Goff B et al. Management of early stage cervical cancer. UpToDate, sist oppdatert nov 2018. Siden besøkt 15.01.2019. www.uptodate.com
Annonse
Annonse